R&D channel feed

Flag­ship start­up Em­press Ther­a­peu­tics launch­es to search for small mol­e­cule drug leads in mi­cro­bial DNA

Last year
Financing
Startups

De­nali claims a neu­ro­fil­a­ment vic­to­ry in Hunter syn­drome, two years af­ter let­ting down Wall Street

Last year

Lil­ly inks $2.4B cash deal to buy DICE and its im­munol­o­gy pipeline

Last year
Deals

Bavar­i­an Nordic's pur­chase of Emer­gen­t's late-stage Chikun­gun­ya vac­cine pays off in PhI­II read­out

Last year

Ar­cel­lx's cell ther­a­py is on hold af­ter pa­tient death in mul­ti­ple myelo­ma tri­al

Last year
Cell/Gene Tx

As­traZeneca scraps oral GLP-1 af­ter PhI ‘does not meet that am­bi­tion’ of trump­ing the com­pe­ti­tion

Last year
Pharma

F2G gets re­ject­ed by the FDA, which wants more da­ta be­fore it will ap­prove an­ti­fun­gal drug, com­pa­ny says

Last year
FDA+

Rhythm’s Im­civree shows off con­tin­ued BMI de­crease in rare obe­si­ty con­di­tion

Last year

Mer­ck clos­es $10.8B deal with Prometheus

Last year

Eli Lil­ly’s mi­graine pre­ven­tion drug Em­gal­i­ty not su­pe­ri­or to Pfiz­er’s Nurtec ODT in head-to-head

Last year
Pharma

Keytru­da com­bi­na­tion hits pri­ma­ry end­point in a rare form of gas­tric can­cer

Last year

Twist Bio­science lays off 212 staffers, most­ly in San Fran­cis­co

Last year

FDA ap­proves Roche’s sec­ond CD20xCD3 bis­pe­cif­ic in cer­tain lym­phomas

Last year
Pharma

FDA de­lays de­ci­sion on GSK blood can­cer drug at heart of $1.9B Sier­ra On­col­o­gy deal

Last year
Pharma

Prime Med­i­cine con­sid­ers fo­cus on au­toim­mune dis­eases for CAR-T, CEO says

Last year
Cell/Gene Tx

Corvus touts ear­ly da­ta on T cell lym­phoma drug, makes PhI­II plans

Last year

Mer­sana slapped with par­tial FDA hold af­ter five pa­tient deaths in ovar­i­an can­cer stud­ies

Last year
FDA+

To sN­DA or NDA? Aldeyra clears a sec­ond PhI­II for sea­son­al al­ler­gy eye drop

Last year

'Mod­er­na will be a rare dis­ease com­pa­ny,' CEO says, as mR­NA com­pa­ny plots ex­pan­sion in ge­net­ic dis­eases and eyes n-of-1 treat­ments

Last year
Pharma
In Focus

Pfiz­er re­files Seagen ac­qui­si­tion pa­per­work, deal still ex­pect­ed to close with­in the year

Last year

Three chil­dren with leukemia treat­ed with first base-edit­ed cell ther­a­py; one died from in­fec­tion

Last year

Ku­ra plans to sell $100M of shares on the back of in­ter­im read­out of acute myeloid leukemia drug

Last year

Ax­some re­ports de­lay to PhI­II nar­colep­sy study, un­veils peak sales es­ti­mates on its drugs

Last year

Pa­tient death leads Seat­tle Chil­dren’s to pause study of 2sev­en­ty bio’s CAR-T cell ther­a­py 

Last year
Cell/Gene Tx
First page Previous page 79808182838485 Next page Last page
A service from the Financial Times